Estimation of global insulin use for type 2 diabetes, 2018–30: a microsimulation analysis

Publication date: Available online 21 November 2018Source: The Lancet Diabetes & EndocrinologyAuthor(s): Sanjay Basu, John S Yudkin, Sylvia Kehlenbrink, Justine I Davies, Sarah H Wild, Kasia J Lipska, Jeremy B Sussman, David BeranSummaryBackgroundThe amount of insulin needed to effectively treat type 2 diabetes worldwide is unknown. It also remains unclear how alternative treatment algorithms would affect insulin use and disability-adjusted life-years (DALYs) averted by insulin use, given that current access to insulin (availability and affordability) in many areas is low. The aim of this study was to compare alternative projections for and consequences of insulin use worldwide under varying treatment algorithms and degrees of insulin access.MethodsWe developed a microsimulation of type 2 diabetes burden from 2018 to 2030 across 221 countries using data from the International Diabetes Federation for prevalence projections and from 14 cohort studies representing more than 60% of the global type 2 diabetes population for HbA1c, treatment, and bodyweight data. We estimated the number of people with type 2 diabetes expected to use insulin, international units (IU) required, and DALYs averted per year under alternative treatment algorithms targeting HbA1c from 6·5% to 8%, lower microvascular risk, or higher HbA1c for those aged 75 years and older.FindingsThe number of people with type 2 diabetes worldwide was estimated to increase from 405·6 million (95% CI 315·3 million–533Â...
Source: The Lancet Diabetes and Endocrinology - Category: Endocrinology Source Type: research